ITGAV and retinoblastoma: DNX-2401, also preclinically known as D24-RGD, is a type 5 human adenovirus genetically modified to target cells expressing alpha-V integrins and replicating in cycling cells and cells with abnormalities in their retinoblastoma (RB) pathway, providing tumor specificity [15,19].